Endogenous Opioids and Opioid Antagonists in Endotoxic and Septic Shock: A Current Perspective

  • J. W. Holaday
  • N. J. Gurll
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 16)

Abstract

For several years after their discovery in 1975, the endogenous opioids (or “endorphins”) were at the forefront of investigations characterizing the role of peptides in biology and medicine. In 1978, it was first proposed that endogenous opioid systems were involved in endotoxic shock [1] and other forms of critical illnesses. In retrospect, the postulation was simple: that the “morphine-like” substances within the body could be released in excessive amounts by the severe physiological stress of shock and trauma; this “overdose” of endogenous opioids would contribute to the decreased cardiovascular function and organ perfusion that characterize shock [2]. The availability of naloxone (Narcan), a competitive antagonist that selectively blocks or reverses the actions of morphine or endogenous opioids, provided an opportunity to test this hypothesis. The first several preclinical and clinical publications clearly demonstrated that naloxone, administered following the onset of shock, improved arterial pressure and other hemodynamic endpoints and, in some studies, survival. By inference, evidence indicated that the body’s own opiate “painkillers” were indeed involved in the pathogenesis of endotoxic or septic shock.

Keywords

Morphine Adenosine Epinephrine Alkaloid Catecholamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Holaday JW, Faden AI (1978) Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature 275:450–451PubMedCrossRefGoogle Scholar
  2. 2.
    Holaday JW, Malcolm DS (1988) Endogenous opioids and other peptides: Evidence for their clinical relevance in shock and CNS injury. In: Chernow B, Holaday JW, Zaloga G, Zaritsky A (eds) Pharmacologic approach to the critically ill patient, 2nd edn. William & Wilkins, Baltimore, pp 718–732Google Scholar
  3. 3.
    Bernton EW, Long JB, Holaday JW (1985) Opioids and neuropeptides: Mechanisms in circulatory shock. Fed Proc 44:290–299PubMedGoogle Scholar
  4. 4.
    Gurll NJ (1992) Endogenous opiates in septic-endotoxic shock. In: Neugebauer E, Holaday JW (eds) Handbook on mediators in septic shock. CRC Press, Florida (in press)Google Scholar
  5. 5.
    Holaday JW, Porreca F, Rothman RB (1991) Functional coupling among opioid receptor types. In: Estefanos F (ed) Opioids in anesthesia II. Butterworth-Heineman, Boston, pp 50–60Google Scholar
  6. 6.
    Reynolds DG, Gurll NJ, Vargish T, Lechner R, Faden AI, Holaday JW (1980) Blockade of opiate receptors with naloxone improves survival and cardiac performance in canine endo-toxic shock. Circ Shock 7:39–48PubMedGoogle Scholar
  7. 7.
    Gurll NJ, Reynolds DG, Holaday JW (1988) Evidence for a role of endorphins in the cardiovascular pathophysiology of primate shock. Crit Care Med 16:521–524PubMedCrossRefGoogle Scholar
  8. 8.
    Gurll NJ (1985) Endorphins in endotoxic shock. In: Proctor RA, Hinshaw LB (eds) Handbook of endotoxin Vol II. Elsevier, Amsterdam, pp 299–310Google Scholar
  9. 9.
    Faden AI, Holaday JW (1980) Naloxone treatment of endotoxin shock: Stereospecificity of physiologic and pharmacologic effects in the rat. J Pharm Exp Ther 212:441–447Google Scholar
  10. 10.
    D’Amato RJ, Holaday JW (1984) Multiple opiate receptors in endotoxic shock: Evidence for d involvement and m — d interactions in vivo. Proc Natl Acad Sci 81:2898–2901PubMedCrossRefGoogle Scholar
  11. 11.
    Holaday JW (1984) Neuropeptides in shock and traumatic injury: Sites and mechanisms of action. Neuroendo Perspectives 3:161–199Google Scholar
  12. 12.
    Lechner RB, Gurll NJ, Reynolds DG (1985) Naloxone potentiates the cardiovascular effects of catecholamines in canine hemorrhagic shock. Circ Shock 16:347–361PubMedGoogle Scholar
  13. 13.
    Holaday JW (1983) Cardiovascular effects of the endogenous opiate system. Ann Rev Pharm Tox 23:541–594CrossRefGoogle Scholar
  14. 14.
    Malcolm DS, Zaloga GP, Willey SC, Holaday JW (1988) Naloxone potentiates epinephrine’s hypertensive effects in endotoxemic rats. Circ Shock 25:259–265PubMedGoogle Scholar
  15. 15.
    Harbour DV, Galin FS, Hughes TK, Smith EM, Blalock JE (1991) Role of leukocyte-derived pro-opiomelanocortin peptides in endotoxic shock. Circ Shock 35:181–191PubMedGoogle Scholar
  16. 16.
    Holaday JW, Bryant HU, Kenner JR, Bernton EW (1989) Brain, endocrine and immune interactions: Implications in intensive care. In: Holaday JW, Bihari D (eds) Brain Failure: Update in Intensive Care and Emergency Medicine, vol 9. Springer-Verlag, New York, pp 1–13Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. W. Holaday
  • N. J. Gurll

There are no affiliations available

Personalised recommendations